X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
FB2001 (bofutrelvir) has demonstrated in vivo antiviral activity in the lung and brain tissue of SARS-CoV-2 mouse model without the need for pharmacokinetic boosting.
Lead Product(s): Bofutrelvir
Therapeutic Area: Infections and Infectious Diseases Product Name: FB2001
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Details:
Subject to the terms of the agreement, Frontier Biotechnologies will be responsible for all development costs for AFFITOPE® AT04 occurring in Greater China and will receive the rights to develop, manufacture and exclusively commercialize AT04 in the licensed territory.
Lead Product(s): Affitope AT04,Aluminium Oxyhydroxide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Affitope AT04
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Affiris
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 22, 2021
Details:
The results of the randomized controlled, open-labelled, multicenter, non-inferiority study showed successful achievement of the primary endpoint, with a good proportion of patients on the ABT regimen with HIV RNA less than 50 copies/mL at 48 weeks.
Lead Product(s): Albuvirtide,Lopinavir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Aikening
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
